Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune-targeted Combination With ALL-like Chemotherapy for Adult ALAL
NCT06991920Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2026
- Primary completion
- Apr 2030
- Modality
- Antibody Conjugates, scFv Fragments, Small Molecules
01
Overview
Open-label, single-arm trial of blinatumomab and venetoclax in acute leukemia of ambiguous lineage (ALAL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Overall Survival at 2 years. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
blinatumomabvenetoclax
03
Conditions
acute leukemia of ambiguous lineage (ALAL)
Beyond the preview
Go deeper on NCT06991920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06991920.